SAB Biotherapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.9%projected annual EPS growth
Analyst Coverage
11analysts covering
FY EPS (est.)
-$1.28next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| SAFEGUARD Phase 2b Trial Enrollment Completion | 31 Dec 2026 |
| SAFEGUARD Phase 2b Topline Data Readout | 31 Dec 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Available-for-Sale Securities Quarterly217.6MTarget: Sufficient to fund operations through 2028
SAFEGUARD Trial Patient Enrollment QuarterlyTarget: 159 patients
Quarterly Research and Development (R&D) Expenses Quarterly13.4MTarget: Managed in line with SAFEGUARD trial progression
Watch Items
- SAFEGUARD Phase 2b Trial Enrollment CompletionTrigger: Completion of enrollment of 159 patients by end of 2026Action: Monitor clinical trial site activations and investigator engagement across the US, UK, EU, Australia, and New Zealand.
- Regulatory Pathway and FDA Accelerated Approval AlignmentTrigger: FDA confirmation of C-peptide AUC as a surrogate endpointAction: Maintain ongoing regulatory discussions with the FDA to prepare for accelerated approval filing based on Phase 2b data.
- Strategic Manufacturing Scale-up with Emergent BioSolutionsTrigger: Execution of process development and clinical/commercial manufacturing milestones for SAB-142Action: Track progress of tech transfer and manufacturing readiness to support potential commercial launch.
Research as of 20 Jun 2026